AustriaAustria

Ugimer money

17.08.2011

Innsbruck – Austrian specialist for so-called ugimeres, Ugichem GmbH, has landed fresh funding. Along with V+ GmbH and the Austrian Research Promotion Agency, Swiss private investors invested about EUR2m to develop the first preclinical candidates for the company’s Ugimer gene-silencing drugs. “We are happy to secure this funding, which gives us the opportunity to build up the Ugimers as a therapeutic gene-silencing product platform in a comprehensive manner,“ said Ugichem CEO Holger Bock. Ugimers are synthetic antisense oligonucleotides that do not require a delivery system to access their target. Ugichem hopes that they will also be able to target cellular compartments that are not accessible through other (RNA) drugs.

AustriaAustria

03.11.2010

Vienna – Austrian vaccine specialist Intercell AG has landed a new partner for its therapeutic vaccine IC41 against chronic infections with the hepatitis C virus (HCV) after Novartis quit a a 270m partnership with the firm this...

AustriaAustria

16.09.2010

Bremen/Vienna/Galway – A novel protein glue that helps colonies of the barnacle Dosima fascicularis to float on the surface of the water and stick to vessels could inspire the next revolution in medicine and material sciences....

AustriaAustria

18.08.2010

Vienna – Austrian vaccine specialist Intercell AG increased R&D spending by 24% in the second quarter of 2010 to EUR16.9m due to expenditures linked to clinical Phase III testing of its traveller's diarrhoea vaccine. That...

AustriaAustria

19.07.2010

An estimated 20,000 participants from over 185 countries are taking part in the 18th International AIDS Conference that began in Vienna on Sunday. The head of the International AIDS Society, and conference chairman, Julio...

AustriaAustria

14.07.2010

Vienna – Swissmedic has approved IXIARO®, a vaccine against Japanese encephalitis from Intercell AG that is distributed and marketed by Novartis AG. The decision by the Swiss authorities is another important milestone for the...

AustriaAustria

10.07.2010

Vienna – Austria’s Intercell AG has closed the acquisition of Cytos’ platform technology for monoclonal antibody discovery, which is based on expression cloning of monoclonal antibodies from human B-cells. As per agreed terms,...

AustriaAustria

12.05.2010

Vienna – Invoking the EU’s safeguard clause, the Austrian parliament has unanimously instructed its Ministry of Health to establish a specific legal measure to prohibit the cultivation of the biotech potato Amflora in the...

AustriaAustria

07.05.2010

Vienna – Austrian Intercell AG expands its current vaccine business to anti-infective monoclonal antibodies. In a EUR 15 million deal Intercell has bought Cytos' antibody discovery platform technology, the firm announced on 6th...

AustriaAustria

08.03.2010

Vienna – GlaxoSmithKline, the se­cond largest drugmaker in the world, has closed its third drug development cooperation in Vienna in just over a year. After signing agreements with Intercell AG and Affiris GmbH, GSK is now to pay...

Displaying results 21 to 30 out of 116

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-austria/browse/2/article/ugimer-money.html

Events

All Events

Stock list

All quotes

TOP

  • CO.DON2.84 EUR4.80%
  • VITA 343.98 EUR4.19%
  • MEDIGENE4.07 EUR2.26%

FLOP

  • THERAMETRICS0.08 CHF-11.11%
  • CYTOS0.24 CHF-4.00%
  • BASILEA97.25 CHF-1.22%

TOP

  • SANTHERA93.80 CHF46.3%
  • CO.DON2.84 EUR19.3%
  • FORMYCON8.22 EUR18.8%

FLOP

  • EVOTEC3.09 EUR-17.6%
  • MEDIGENE4.07 EUR-13.8%
  • 4SC1.16 EUR-12.8%

TOP

  • SANTHERA93.80 CHF2036.7%
  • CO.DON2.84 EUR226.4%
  • PAION2.69 EUR158.7%

FLOP

  • CYTOS0.24 CHF-94.0%
  • THERAMETRICS0.08 CHF-46.7%
  • MERCK KGAA67.56 EUR-41.3%

No liability assumed, Date: 15.09.2014


Current issue

All issues

Product of the week

Products